Clinical characteristics of patients responding or not responding to first-line treatment (univariate analysis)
Characteristic . | Responders . | Nonresponders . | P . |
|---|---|---|---|
| Donor type, no. | |||
| HLA-identical sibling | 80 | 30 | — |
| Unrelated | 70 | 31 | .5 |
| Median donor age, y (range) | 36 (2-73) | 42 (7-66) | .1 |
| Female donor/male recipient, no. (%) | 39 (26) | 10 (16) | .1 |
| Median recipient age, y (range) | 32 (6-66) | 34 (2-64) | .2 |
| Disease | |||
| Early disease, no. (%) | 73 (49) | 21 (35) | .06 |
| Conditioning with TBI, no. (%) | 96 (64) | 39 (66) | .2 |
| No. of cells infused, × 108/kg (range) | 4.6 (0.7-12.2) | 4.6 (6.0-17) | .1 |
| GvHD prophylaxis CsA MTX, no. (%) | 146 (98) | 59 (97) | .8 |
| Grade of GvHD at registration, no. | |||
| I | 91 | 24 | — |
| II | 49 | 27 | — |
| III to IV | 10 | 10 | .008 |
| Interval from Tx to GvHD, d (range) | 16 (7-42) | 17 (8-63) | .1 |
| Alive, no. (%) | 84 (56) | 22 (36) | .02 |
| Follow-up surviving patients, no. (range) | 1176 (129-1930) | 1134 (37-1969) | .8 |
| Follow-up deceased patients, no. (range) | 203 (9-1809) | 101 (15-1056) | .3 |
| Transplant-related deaths, no. (%) | 40 (27) | 30 (49) | .001 |
| Leukemia-related deaths, no. (%) | 26 (17) | 9 (15) | .4 |
Characteristic . | Responders . | Nonresponders . | P . |
|---|---|---|---|
| Donor type, no. | |||
| HLA-identical sibling | 80 | 30 | — |
| Unrelated | 70 | 31 | .5 |
| Median donor age, y (range) | 36 (2-73) | 42 (7-66) | .1 |
| Female donor/male recipient, no. (%) | 39 (26) | 10 (16) | .1 |
| Median recipient age, y (range) | 32 (6-66) | 34 (2-64) | .2 |
| Disease | |||
| Early disease, no. (%) | 73 (49) | 21 (35) | .06 |
| Conditioning with TBI, no. (%) | 96 (64) | 39 (66) | .2 |
| No. of cells infused, × 108/kg (range) | 4.6 (0.7-12.2) | 4.6 (6.0-17) | .1 |
| GvHD prophylaxis CsA MTX, no. (%) | 146 (98) | 59 (97) | .8 |
| Grade of GvHD at registration, no. | |||
| I | 91 | 24 | — |
| II | 49 | 27 | — |
| III to IV | 10 | 10 | .008 |
| Interval from Tx to GvHD, d (range) | 16 (7-42) | 17 (8-63) | .1 |
| Alive, no. (%) | 84 (56) | 22 (36) | .02 |
| Follow-up surviving patients, no. (range) | 1176 (129-1930) | 1134 (37-1969) | .8 |
| Follow-up deceased patients, no. (range) | 203 (9-1809) | 101 (15-1056) | .3 |
| Transplant-related deaths, no. (%) | 40 (27) | 30 (49) | .001 |
| Leukemia-related deaths, no. (%) | 26 (17) | 9 (15) | .4 |
For responders, n = 150 (71%); for nonresponders, n = 61 (29%).
Tx indicates transplantation; —, not applicable.